Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.47 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL6237182 | 0.96 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL15845334 | 0.96 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL142870 | 0.96 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL15842973 | 0.96 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL2916896 | 0.96 | CA4 (0.50) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL11272877 | 0.93 | CA4 (0.41) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL22948 | 0.92 | — | — | |
| Glycine SCHEMBL5712834 | 0.92 | CA4 (0.47) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL7199765 | 0.92 | — | — | |
| Glycine SCHEMBL21747591 | 0.92 | CA4 (0.47) | CA4GLRA1SLC6A9OR51E2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3472 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074667-A | Nanometer oral liquid for sports nutrition, and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-12636281-B2 | Dietary supplements to ameliorate dietary inadequacies related to brain health or neurodegenerative diseases, and methods to design dietary supplements | NEURORESERVE INC. (US) | 2026-05-26 | — | — | US | claimed |
| CN-122056386-A | Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122030612-A | Shear-resistant slow-release microcapsule powder and preparation method and application thereof | 大连医诺生物股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| US-20260130927-A1 | PERMEABILITY ENHANCED ORAL THERAPY DELIVERY SYSTEM, AND METHOD OF MANUFACTURE | STELTING SCOTT ALAN (US) | 2026-05-14 | — | — | US | claimed |
| US-20260130850-A1 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | LIFEACTIVE INC (US) | 2026-05-14 | — | — | US | claimed |
| CN-122005911-A | Hemostatic sponge with antibacterial and osteogenic properties, and preparation method and application thereof | 上海师范大学 | 2026-05-12 | — | — | CN | claimed |
| CN-122010084-A | Compact porous carbon material and preparation method and application thereof | 溧阳天目先导电池材料科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260123649-A1 | COMPOSITIONS AND METHODS FOR NUTRACEUTICAL GUMMY | NOON WORLD INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260124252-A1 | Dietary Pattern Directed Nutritional Supplementation Composition and Methods for Attenuating Age-Related Cognitive Decline or Enhancing Cognitive Function | NEURORESERVE INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-0693280-A2 | Apparatus and process for strengthening low density compression dosage units and products therefrom | FUISZ TECHNOLOGIES LTD. (US) | 1996-01-24 | — | — | EP | claimed |
| EP-0578768-B1 | INGESTIBLE PHARMACEUTICAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL TRACT DISTRESS | PROCTER & GAMBLE (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0600725-A1 | Pharmaceutical compositions containing a guanidinothiazole and antacids | McNEIL-PPC, INC. (US) | 1994-06-08 | — | — | EP | claimed |
| EP-0578768-A1 | INGESTIBLE PHARMACEUTICAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL TRACT DISTRESS. | PROCTER & GAMBLE (US) | 1994-01-19 | — | — | EP | claimed |
| EP-0578732-A1 | CHEWABLE ANTACID COMPOSITIONS. | PROCTER & GAMBLE (US) | 1994-01-19 | — | — | EP | claimed |
| US-5244670-A | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress | THE PROCTER & GAMBLE COMPANY (US) | 1993-09-14 | — | — | US | claimed |
| WO-1992017164-A1 | INGESTIBLE PHARMACEUTICAL COMPOSITIONS FOR TREATING UPPER GASTROINTESTINAL TRACT DISTRESS | THE PROCTER & GAMBLE COMPANY (US) | 1992-10-15 | — | — | WO | claimed |
| WO-1992017161-A1 | CHEWABLE ANTACID COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1992-10-15 | — | — | WO | claimed |
| US-4937076-A | CHOCOLATE OR HYDROGENATED TALLOW AS COATING AND BINDER; STORAGE STABILITY | COMBE INCORPORATED (US) | 1990-06-26 | — | — | US | claimed |
| US-4021536-A | Magnesium-zirconium complexes useful as antiperspirants | ARMOUR PHARMACEUTICAL COMPANY (US) | 1977-05-03 | — | — | US | claimed |